Journal
TRENDS IN IMMUNOLOGY
Volume 33, Issue 5, Pages 231-237Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.it.2012.02.009
Keywords
CD73; adenosine; cancer; immunity
Categories
Funding
- National Health and Medical Research Council (NH&MRC) of Australia
- Victorian Breast Cancer Consortium
- Victorian Cancer Agency
Ask authors/readers for more resources
Tumors use several strategies to evade immunosurveillance. One such mechanism is the generation of adenosine within the tumor microenvironment, which potently suppresses antitumor T cell responses. Adenosine within the tumor is generated by CD73, a membrane-bound nucleotidase that is expressed by tumor cells, suppressive immune subsets such as T regulatory cells (Tregs) and myeloid-derived suppressor cells and endothelial cells. Recent evidence suggests that targeted inhibition of CD73 has the potential to reduce tumorigenesis and metastasis, as well as enhancing the potency of T-cell-directed therapies. This review outlines the impact of adenosine on suppressing the antitumor response and the evidence supporting the rationale for CD73 targeting in the treatment of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available